Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India
· Delayed Price · Currency is INR 1,120.00
-6.40 (-0.57%)
Jun 17, 2025, 3:30 PM IST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
| Radiopharma | 30.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Radiopharma Growth | 17.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Organisation - Sterile Injectables | 11.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Organisation - Sterile Injectables Growth | -3.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research, and Development and Manufacturing Organisation | 10.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research, and Development and Manufacturing Organisation Growth | -7.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics | 7.75B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics Growth | 1.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Allergy Immunotherapy | 6.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Allergy Immunotherapy Growth | 12.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Management Services | 383.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Management Services Growth | 75.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Novel Drugs | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Novel Drugs Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research and Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research and Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Science Ingredients | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Science Ingredients Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Discovery and Development Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
| Americas and Europe | 60.12B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas and Europe Growth | 7.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World | 4.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World Growth | 0.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India | 1.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India Growth | 0.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Global | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|